Victor M Lu1, John P Welby2, Anita Mahajan3, Nadia N Laack3, David J Daniels4. 1. Department of Neurosurgery, Mayo Clinic, 200 First St. SW, Rochester, MN, USA. lu.victor@mayo.edu. 2. Department of Neurosurgery, Mayo Clinic, 200 First St. SW, Rochester, MN, USA. 3. Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA. 4. Department of Neurosurgery, Mayo Clinic, 200 First St. SW, Rochester, MN, USA. daniels.david@mayo.edu.
Abstract
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor with dismal prognosis despite initial radiation therapy (RT). The clinical consequences of attempting reirradiation (reRT) in these patients to alleviate both symptomatology and improve prognosis are currently unclear. Thus, the aim of this systematic review and meta-analysis was to clarify the efficacy and safety of reRT in DIPG. METHODS: Searches of seven electronic databases from inception to January 2019 were conducted following the appropriate guidelines. Articles were screened against prespecified criteria. The incidence and duration of clinical outcomes were then extracted and pooled by means of meta-analysis from the included studies. RESULTS: A total of 7 studies satisfied all criteria, describing 90 cases of DIPG in which reRT was attempted 11.8-14 months after initial RT. Based on a random-effects model, the incidences of clinical improvement and radiologic response following reRT were 87% (95% CI, 78-95%) and 69% (95% CI, 52-84%), respectively. The incidence of acute serious toxicity was 0% (95% CI, 0-4%). Pooled overall survivals from initial diagnosis and time of reRT were 18.0 months (95% CI, 14.2-21.7) and 6.2 months (95% CI, 5.5-7.0), respectively. CONCLUSIONS: Based on these results, the clinical consequences of reRT for DIPG when administered appropriately and safely at first progression appear acceptable, and potentially favorable, based on the limited evidence in the current literature. Concerns regarding acute serious toxicity were not realized. It is likely that a subcohort of all DIPG diagnoses will be most amenable to improve prognosis with reRT, and greater investigation is required to identify their characteristics.
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor with dismal prognosis despite initial radiation therapy (RT). The clinical consequences of attempting reirradiation (reRT) in these patients to alleviate both symptomatology and improve prognosis are currently unclear. Thus, the aim of this systematic review and meta-analysis was to clarify the efficacy and safety of reRT in DIPG. METHODS: Searches of seven electronic databases from inception to January 2019 were conducted following the appropriate guidelines. Articles were screened against prespecified criteria. The incidence and duration of clinical outcomes were then extracted and pooled by means of meta-analysis from the included studies. RESULTS: A total of 7 studies satisfied all criteria, describing 90 cases of DIPG in which reRT was attempted 11.8-14 months after initial RT. Based on a random-effects model, the incidences of clinical improvement and radiologic response following reRT were 87% (95% CI, 78-95%) and 69% (95% CI, 52-84%), respectively. The incidence of acute serious toxicity was 0% (95% CI, 0-4%). Pooled overall survivals from initial diagnosis and time of reRT were 18.0 months (95% CI, 14.2-21.7) and 6.2 months (95% CI, 5.5-7.0), respectively. CONCLUSIONS: Based on these results, the clinical consequences of reRT for DIPG when administered appropriately and safely at first progression appear acceptable, and potentially favorable, based on the limited evidence in the current literature. Concerns regarding acute serious toxicity were not realized. It is likely that a subcohort of all DIPG diagnoses will be most amenable to improve prognosis with reRT, and greater investigation is required to identify their characteristics.
Authors: Sebastian Bender; Yujie Tang; Anders M Lindroth; Volker Hovestadt; David T W Jones; Marcel Kool; Marc Zapatka; Paul A Northcott; Dominik Sturm; Wei Wang; Bernhard Radlwimmer; Jonas W Højfeldt; Nathalène Truffaux; David Castel; Simone Schubert; Marina Ryzhova; Huriye Seker-Cin; Jan Gronych; Pascal David Johann; Sebastian Stark; Jochen Meyer; Till Milde; Martin Schuhmann; Martin Ebinger; Camelia-Maria Monoranu; Anitha Ponnuswami; Spenser Chen; Chris Jones; Olaf Witt; V Peter Collins; Andreas von Deimling; Nada Jabado; Stephanie Puget; Jacques Grill; Kristian Helin; Andrey Korshunov; Peter Lichter; Michelle Monje; Christoph Plass; Yoon-Jae Cho; Stefan M Pfister Journal: Cancer Cell Date: 2013-10-31 Impact factor: 31.743
Authors: David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily Journal: Acta Neuropathol Date: 2015-09-23 Impact factor: 17.088
Authors: Sophie E M Veldhuijzen van Zanten; Ofelia Cruz; Gertjan J L Kaspers; Darren R Hargrave; Dannis G van Vuurden Journal: J Neurooncol Date: 2016-05-13 Impact factor: 4.130
Authors: Lara Chavaz; Geert O Janssens; Stephanie Bolle; Henry Mandeville; Monica Ramos-Albiac; Karen Van Beek; Helen Benghiat; Bianca Hoeben; Andres Morales La Madrid; Clemens Seidel; Rolf-Dieter Kortmann; Darren Hargrave; Lorenza Gandola; Emilia Pecori; Dannis G van Vuurden; Veronica Biassoni; Maura Massimino; Christof M Kramm; Andre O von Bueren Journal: Front Oncol Date: 2022-06-22 Impact factor: 5.738
Authors: Julian S Rechberger; Erica A Power; Victor M Lu; Liang Zhang; Jann N Sarkaria; David J Daniels Journal: Neurosurg Focus Date: 2020-01-01 Impact factor: 4.047
Authors: Joshua D Bernstock; Samantha E Hoffman; Ari D Kappel; Pablo A Valdes; Walid Ibn Essayed; Neil V Klinger; Kyung-Don Kang; Stacie K Totsch; Hannah E Olsen; Charles W Schlappi; Katharina Filipski; Florian A Gessler; Lissa Baird; Mariella G Filbin; Rintaro Hashizume; Oren J Becher; Gregory K Friedman Journal: Oncoimmunology Date: 2022-09-26 Impact factor: 7.723